

WEST Search History

DATE: Friday, September 05, 2003

<u>Hide?</u>	<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>
<i>DB=PGPB,USPT,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>			
<input type="checkbox"/>	L7	L6 and (quartnerary ammoni?)	11
<input type="checkbox"/>	L6	L5 and ((polyethylene glycol) or (hydroxy stearic) or (acid glyceride?))	34
<input type="checkbox"/>	L5	L3 and (deionized water)	34
<input type="checkbox"/>	L4	L3 and (nipagin or nipasol)	1
<input type="checkbox"/>	L3	L2 and ((propylene glycol) or glerol or glycol\$)	35
<input type="checkbox"/>	L2	L1 and (acetate? or citrate? or ascorbate? or phosphate?)	36
<input type="checkbox"/>	L1	ibandron\$ and (osteogen\$ or bone or osseous or skeletal\$)	253

END OF SEARCH HISTORY

Connecting via Winsock to STN

Welcome to STN International! Enter x:

x

Welcome to STN International! Enter x:

LOGINID: sssptau153cxa

PASSWORD :

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * * * * Welcome to STN International * * * * * * * * * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 Feb 24 PCTGEN now available on STN
NEWS 4 Feb 24 TEMA now available on STN
NEWS 5 Feb 26 NTIS now allows simultaneous left and right truncation
NEWS 6 Feb 26 PCTFULL now contains images
NEWS 7 Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 8 Mar 24 PATDPAFULL now available on STN
NEWS 9 Mar 24 Additional information for trade-named substances without structures available in REGISTRY
NEWS 10 Apr 11 Display formats in DGENE enhanced
NEWS 11 Apr 14 MEDLINE Reload
NEWS 12 Apr 17 Polymer searching in REGISTRY enhanced
NEWS 13 AUG 22 Indexing from 1927 to 1936 added to records in CA/CAPLUS
NEWS 14 Apr 21 New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS 15 Apr 28 RDISCLOSURE now available on STN
NEWS 16 May 05 Pharmacokinetic information and systematic chemical names added to PHAR
NEWS 17 May 15 MEDLINE file segment of TOXCENTER reloaded
NEWS 18 May 15 Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS 19 May 19 Simultaneous left and right truncation added to WSCA
NEWS 20 May 19 RAPRA enhanced with new search field, simultaneous left and right truncation
NEWS 21 Jun 06 Simultaneous left and right truncation added to CBNB
NEWS 22 Jun 06 PASCAL enhanced with additional data
NEWS 23 Jun 20 2003 edition of the FSTA Thesaurus is now available
NEWS 24 Jun 25 HSDB has been reloaded
NEWS 25 Jul 16 Data from 1960-1976 added to RDISCLOSURE
NEWS 26 Jul 21 Identification of STN records implemented
NEWS 27 Jul 21 Polymer class term count added to REGISTRY
NEWS 28 Jul 22 INPADOC: Basic index (/BI) enhanced; Simultaneous Left and Right Truncation available
NEWS 29 AUG 05 New pricing for EUROPATFULL and PCTFULL effective August 1, 2003
NEWS 30 AUG 13 Field Availability (/FA) field enhanced in BEILSTEIN
NEWS 31 AUG 15 PATDPAFULL: one FREE connect hour, per account, in September 2003
NEWS 32 AUG 15 PCTGEN: one FREE connect hour, per account, in September 2003
NEWS 33 AUG 15 RDISCLOSURE: one FREE connect hour, per account, in September 2003
NEWS 34 AUG 15 TEMA: one FREE connect hour, per account, in September 2003
NEWS 35 AUG 18 Data available for download as a PDF in RDISCLOSURE
NEWS 36 AUG 18 Simultaneous left and right truncation added to PASCAL

NEWS 37 AUG 18 FROSTI and KOSMET enhanced with Simultaneous Left and Right Truncation
NEWS 38 AUG 18 Simultaneous left and right truncation added to ANABSTR

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 15:38:41 ON 05 SEP 2003

=> file caplus uspatful japiro europatful medline biosis embase
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'CAPLUS' ENTERED AT 15:39:10 ON 05 SEP 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 15:39:10 ON 05 SEP 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAPIO' ENTERED AT 15:39:10 ON 05 SEP 2003
COPYRIGHT (C) 2003 Japanese Patent Office (JPO) - JAPIO

FILE 'EUROPATFULL' ENTERED AT 15:39:10 ON 05 SEP 2003
COPYRIGHT (c) 2003 WIWA Verlag Muenchen (WIWA)

FILE 'MEDLINE' ENTERED AT 15:39:10 ON 05 SEP 2003

FILE 'BIOSIS' ENTERED AT 15:39:10 ON 05 SEP 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC (B)

FILE 'EMBASE' ENTERED AT 15:39:10 ON 05 SEP 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved

=> s ibandron? and (osteogen? or bone or osseous or skeletal)
L1 1101 IBANDRON? AND (OSTEOGEN? OR BONE OR OSSEOUS OR SKELETAL)

=> s 11 and (acetate# or citr? or ascorbate# or phosphate#)
L2 285 L1 AND (ACETATE# OR CITR? OR ASCORBATE# OR PHOSPHATE#)

=> s 12 and ((polyethylene glycol) or (propylene glycol) or (acid glyceride#))
UNMATCHED LEFT PARENTHESIS 'AND ((POLYETHYLE'
COMMAND STACK INTERRUPTED. ENTER "DISPLAY HISTORY"
TO SEE WHICH COMMANDS WERE EXECUTED.

The number of right parentheses in a query must be equal to the number of left parentheses.

=> s 12 and ((polyethylene glycol) or (propylene glycol) or (acid glyceride#))
L3 199 L2 AND ((POLYETHYLENE GLYCOL) OR (PROPYLENE GLYCOL) OR (ACID GLYCERIDE#))

=> s 13 and (nipagin or nipasol or borate? or boric?)
L4 47 L3 AND (NIPAGIN OR NIPASOL OR BORATE? OR BORIC?)

=> s 14 and (deionized water)
L5 20 L4 AND (DEIONIZED WATER)

=> s 15 and (sorbitol or sweetener# or adjvant# or excipient#)
L6 20 L5 AND (SORBITOL OR SWEETENER# OR ADJVANT# OR EXCIPIENT#)

=> d 16 1-20 ibib abs

L6 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:591663 CAPLUS
DOCUMENT NUMBER: 137:129921
TITLE: Liquid pharmaceutical composition containing
ibandronate for treating bone
diseases
INVENTOR(S): Urias, Guadalupe Martinez
PATENT ASSIGNEE(S): Riderway Corporation, Panama
SOURCE: Eur. Pat. Appl., 11 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|----------|
| EP 1228761 | A2 | 20020807 | EP 2002-1959 | 20020201 |
| EP 1228761 | A3 | 20030115 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| US 2002142997 | A1 | 20021003 | US 2002-66008 | 20020201 |
| JP 2002332235 | A2 | 20021122 | JP 2002-25725 | 20020201 |
| BR 2002000291 | A | 20030701 | BR 2002-291 | 20020201 |
| PRIORITY APPLN. INFO.: US 2001-265827P P 20010201
AR 2001-106109 A 20011228 | | | | |

AB A liq. pharmaceutical compn. and methods for use in the treating of bone diseases, comprise an aq. soln. contg. 0.05-35% by wt. of ibandronic acid or its salts, 0.1-5% by wt. of a pH regulating agent, 1-15% by wt. of a co-solvent, 0.005%-0.5% by wt. of a conserving agent, 1-90% by wt. of a deionized water, and excipients and pharmaceutically acceptable stabilizers, wherein the compn. has a pH of about 2-7. The compn. is formulated for sublingual administration and enteric administration. For example, a compn. for sublingual administration was prep'd. by dissolving 1200 mg of monohydrate citric acid in deionized water to obtain equiv. to 22%, adding 2810 mg of aq. sodium ibandronate followed by 20 mg of propylene glycol with agitation, adjusting the pH to 2.4, and adding deionized water to bring the formulation to 100 g followed by filtering.

L6 ANSWER 2 OF 20 USPATFULL on STN
ACCESSION NUMBER: 2002:259424 USPATFULL
TITLE: Liquid pharmaceutical composition for treating
bone diseases
INVENTOR(S): Urias, Guadalupe Martinez, Buenos Aires, ARGENTINA

PATENT ASSIGNEE(S) : RIDERWAY CORPORATION (non-U.S. corporation)

| | NUMBER | KIND | DATE |
|---------------------|---------------|------|---------------|
| PATENT INFORMATION: | US 2002142997 | A1 | 20021003 |
| APPLICATION INFO.: | US 2002-66008 | A1 | 20020201 (10) |

| | NUMBER | DATE |
|-----------------------|---|---------------|
| PRIORITY INFORMATION: | US 2001-265827P | 20010201 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | APPLICATION | |
| LEGAL REPRESENTATIVE: | DARBY & DARBY P.C., 805 Third Avenue, New York, NY, 10022 | |
| NUMBER OF CLAIMS: | 16 | |
| EXEMPLARY CLAIM: | 1 | |
| LINE COUNT: | 620 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a liquid pharmaceutical composition and methods for use in the treating of bone diseases, the composition being an aqueous solution comprising 0.05% to 35% by weight of ibandronic acid or salts thereof; 0.1% to 5% by weight of a pH regulating agent; 1% to 15% by weight of a co-solvent; 0.005% to 0.5% by weight of a conserving agent; 1% to 90% by weight of a deionized water; and excipients and pharmaceutically acceptable stabilizers, wherein the composition has a pH of about 2 to 7. The composition is formulated for sublingual administration and enteric administration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 3 OF 20 USPATFULL on STN
ACCESSION NUMBER: 2002:160717 USPATFULL
TITLE: Integrin receptor antagonists
INVENTOR(S): Askew, Ben C., Newbury Park, CA, United States
Smith, Garry R., Limerick, PA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|--------------|
| PATENT INFORMATION: | US 6413955 | B1 | 20020702 |
| APPLICATION INFO.: | US 2000-677677 | | 20001002 (9) |

| | NUMBER | DATE |
|-----------------------|--|---------------|
| PRIORITY INFORMATION: | US 1999-157490P | 19991004 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | GRANTED | |
| PRIMARY EXAMINER: | Shah, Mukund J. | |
| ASSISTANT EXAMINER: | Patel, Sudhaker B. | |
| LEGAL REPRESENTATIVE: | Durette, Philippe L., Winokur, Melvin | |
| NUMBER OF CLAIMS: | 21 | |
| EXEMPLARY CLAIM: | 1 | |
| NUMBER OF DRAWINGS: | 0 Drawing Figure(s); 0 Drawing Page(s) | |
| LINE COUNT: | 3955 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3 and/or .alpha.v.beta.5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammatory

arthritis, cancer, and metastatic tumor growth.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 4 OF 20 USPATFULL on STN

ACCESSION NUMBER: 2002:152632 USPATFULL
TITLE: .alpha.v integrin receptor antagonists
INVENTOR(S): Duggan, Mark E., Schwenksville, PA, United States
Hartman, George D., Lansdale, PA, United States
Meissner, Robert S., Schwenksville, PA, United States
Perkins, James J., Churchville, PA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S.
corporation)

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|--------------|
| PATENT INFORMATION: | US 6410526 | B1 | 20020625 |
| APPLICATION INFO.: | US 2000-583522 | | 20000531 (9) |

| | NUMBER | DATE |
|-----------------------|--|---------------|
| PRIORITY INFORMATION: | US 1999-137101P | 19990602 (60) |
| | US 2000-179216P | 20000131 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | GRANTED | |
| PRIMARY EXAMINER: | Coleman, Brenda | |
| LEGAL REPRESENTATIVE: | Durette, Philippe L., Winokur, Melvin | |
| NUMBER OF CLAIMS: | 28 | |
| EXEMPLARY CLAIM: | 1 | |
| NUMBER OF DRAWINGS: | 0 Drawing Figure(s); 0 Drawing Page(s) | |
| LINE COUNT: | 3656 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel nonanoic acid derivatives, their synthesis, and their use as .alpha.v integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3 and .alpha.v.beta.5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, cancer, and metastatic tumor growth.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 5 OF 20 USPATFULL on STN

ACCESSION NUMBER: 2002:92700 USPATFULL
TITLE: Alpha v integrin receptor antagonists
INVENTOR(S): Arison, Byron H., Watchung, NJ, UNITED STATES
Cui, Donghui, Newton, PA, UNITED STATES
Duggan, Mark E., Schwenksville, PA, UNITED STATES
Halczenko, Wasyl, Lansdale, PA, UNITED STATES
Hutchinson, John H., Philadelphia, PA, UNITED STATES
Prueksaritanont, Thomayant, Lansdale, PA, UNITED STATES
Subramanian, Raju, Perkasie, PA, UNITED STATES
Fang, Xiaojun, Kalamazoo, MI, UNITED STATES

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|--------------|
| PATENT INFORMATION: | US 2002049224 | A1 | 20020425 |
| APPLICATION INFO.: | US 6426353 | B2 | 20020730 |
| | US 2001-952084 | A1 | 20010914 (9) |

| | NUMBER | DATE |
|--|--------|------|
| | | |

PRIORITY INFORMATION: US 2000-232344P 20000914 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
LINE COUNT: 1088

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel compounds formed by metabolic conversion of compounds of structural formula (1), pharmaceutical compositions containing such compounds, and their use as .alpha.v.beta.3 integrin receptor antagonists. The compounds of the present invention are useful for inhibiting bone resorption, restenosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammatory arthritis, cancer, and metastatic tumor growth. They are particularly useful for inhibiting bone resorption and for the treatment and prevention of osteoporosis. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 6 OF 20 USPATFULL on STN
ACCESSION NUMBER: 2002:72890 USPATFULL
TITLE: Alpha V integrin receptor antagonists
INVENTOR(S):
Coleman, Paul J., Wallingford, PA, UNITED STATES
Cui, Donghui, Newtown, PA, UNITED STATES
Duggan, Mark E., Schwenksville, PA, UNITED STATES
Hutchinson, John H., Philadelphia, PA, UNITED STATES
Prueksaritanont, Thomayant, Lansdale, PA, UNITED STATES
Silva Elipe, Maria Victoria, Mountainside, NJ, UNITED STATES
Fang, Xiaojun, Kalamazoo, MI, UNITED STATES

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|--------------|
| PATENT INFORMATION: | US 2002040030 | A1 | 20020404 |
| APPLICATION INFO.: | US 2001-953606 | A1 | 20010914 (9) |

| | NUMBER | DATE |
|-----------------------|---|---------------|
| PRIORITY INFORMATION: | US 2000-232262P | 20000914 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | APPLICATION | |
| LEGAL REPRESENTATIVE: | MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907 | |
| NUMBER OF CLAIMS: | 10 | |
| EXEMPLARY CLAIM: | 1 | |
| LINE COUNT: | 1296 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel compounds formed by metabolic conversion of compounds of the structural formula depicted below (R.dbd.H or Me), pharmaceutical compositions containing such compounds, and their use as .alpha.v.beta.3 integrin receptor antagonists. The compounds of the present invention are useful for inhibiting bone resorption, restenosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammatory arthritis, cancer, and metastatic tumor growth. They are particularly useful for inhibiting bone resorption and for the treatment and prevention of osteoporosis. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 7 OF 20 USPATFULL on STN
ACCESSION NUMBER: 2002:67236 USPATFULL
TITLE: Alpha V integrin receptor antagonists

INVENTOR(S) : Duggan, Mark E., Schwenksville, PA, UNITED STATES
Halczenko, Wasyl, Lansdale, PA, UNITED STATES
Hutchinson, John H., Philadelphia, PA, UNITED STATES
Li, Aiwen, Audubon, PA, UNITED STATES
Meissner, Robert S., Schwenksville, PA, UNITED STATES
Perkins, James J., Churchville, PA, UNITED STATES
Steele, Thomas G., Schwenksville, PA, UNITED STATES
Wang, Jiabing, Chalfont, PA, UNITED STATES
Patane, Michael A., Billerica, MA, UNITED STATES

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|--------------|
| PATENT INFORMATION: | US 2002037889 | A1 | 20020328 |
| | US 6472403 | B2 | 20021029 |
| APPLICATION INFO.: | US 2001-766148 | A1 | 20010119 (9) |

| | NUMBER | DATE |
|-----------------------|---|---------------|
| PRIORITY INFORMATION: | US 2000-177168P | 20000120 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | APPLICATION | |
| LEGAL REPRESENTATIVE: | MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907 | |
| NUMBER OF CLAIMS: | 17 | |
| EXEMPLARY CLAIM: | 1 | |
| LINE COUNT: | 2835 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel imidazolidinone derivatives thereof, their synthesis, and their use as .alpha.v integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3 and/or .alpha.v.beta.5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, cancer, and metastatic tumor growth.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 8 OF 20 USPATFULL on STN
ACCESSION NUMBER: 2002:57802 USPATFULL
TITLE: Integrin receptor antagonists
INVENTOR(S) : Duggan, Mark E., Schwenksville, PA, United States
Hartman, George D., Lansdale, PA, United States
Perkins, James J., Churchville, PA, United States
Ihle, Nathan, Mercer Island, WA, United States
PATENT ASSIGNEE(S) : Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|--------------|
| PATENT INFORMATION: | US 6358970 | B1 | 20020319 |
| APPLICATION INFO.: | US 2000-599088 | | 20000621 (9) |

| | NUMBER | DATE |
|-----------------------|--|---------------|
| PRIORITY INFORMATION: | US 1999-140535P | 19990623 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | GRANTED | |
| PRIMARY EXAMINER: | Dentz, Bernard | |
| LEGAL REPRESENTATIVE: | Durette, Philippe L., Winokur, Melvin | |
| NUMBER OF CLAIMS: | 19 | |
| EXEMPLARY CLAIM: | 1 | |
| NUMBER OF DRAWINGS: | 0 Drawing Figure(s); 0 Drawing Page(s) | |
| LINE COUNT: | 2558 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3 and/or .alpha.v.beta.5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, cancer, and metastatic tumor growth.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 9 OF 20 USPATFULL on STN

ACCESSION NUMBER: 2002:17296 USPATFULL

TITLE: Integrin receptor antagonists

INVENTOR(S):
Askew, Ben C., Lansdale, PA, UNITED STATES
Coleman, Paul J., Wallingford, PA, UNITED STATES
Duggan, Mark E., Schwenksville, PA, UNITED STATES
Halczenko, Wasyl, Lansdale, PA, UNITED STATES
Hartman, George D., Lansdale, PA, UNITED STATES
Hunt, Cecilia A., Plymouth Meeting, PA, UNITED STATES
Hutchinson, John H., Philadelphia, PA, UNITED STATES
Meissner, Robert S., Schwenksville, PA, UNITED STATES
Patane, Michael A., Harleysville, PA, UNITED STATES
Smith, Garry R., Limerick, PA, UNITED STATES
Wang, Jiabing, Lansdale, PA, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2002010176 A1 20020124

APPLICATION INFO.: US 2001-916977 A1 20010728 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1999-454847, filed on 7 Dec 1999, PENDING Division of Ser. No. US 1998-212082, filed on 15 Dec 1998, GRANTED, Pat. No. US 6048861

NUMBER DATE

PRIORITY INFORMATION: US 1997-69899P 19971217 (60)
US 1998-83209P 19980427 (60)
US 1998-92622P 19980713 (60)
US 1998-108063P 19981112 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907

NUMBER OF CLAIMS: 40

EXEMPLARY CLAIM: 1

LINE COUNT: 5336

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5, and/or .alpha.v.beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 10 OF 20 USPATFULL on STN

ACCESSION NUMBER: 2001:233621 USPATFULL

TITLE: Alpha V integrin receptor antagonists

INVENTOR(S) : Askew, Ben C., Newbury Park, CA, United States
Breslin, Michael J., Drexel Hill, PA, United States
Duggan, Mark E., Schwenksville, PA, United States
Hutchinson, John H., Philadelphia, PA, United States
Meissner, Robert S., Schwenksville, PA, United States
Perkins, James J., Churchville, PA, United States
Steele, Thomas G., Schwenksville, PA, United States
Patane, Michael A., Billerica, MA, United States

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|--------------|
| PATENT INFORMATION: | US 2001053853 | A1 | 20011220 |
| APPLICATION INFO.: | US 2001-767471 | A1 | 20010123 (9) |

| | NUMBER | DATE |
|-----------------------|---|---------------|
| PRIORITY INFORMATION: | US 2000-177792P | 20000124 (60) |
| | US 2000-230469P | 20000906 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | APPLICATION | |
| LEGAL REPRESENTATIVE: | MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907 | |
| NUMBER OF CLAIMS: | 24 | |
| EXEMPLARY CLAIM: | 1 | |
| LINE COUNT: | 4132 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel alkanoic acid derivatives thereof, their synthesis, and their use as .alpha.v integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3 and/or .alpha.v.beta.5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammatory arthritis, cancer, and metastatic tumor growth.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 11 OF 20 USPATFULL on STN
ACCESSION NUMBER: 2001:168133 USPATFULL
TITLE: Integrin receptor antagonists
INVENTOR(S) : Duggan, Mark E., Schwenksville, PA, United States
Hartman, George D., Lansdale, PA, United States
Patane, Michael A., Harleysville, PA, United States
PATENT ASSIGNEE(S) : Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|-----------------------|---|------|--------------|
| PATENT INFORMATION: | US 6297249 | B1 | 20011002 |
| APPLICATION INFO.: | US 1999-453847 | | 19991202 (9) |
| RELATED APPLN. INFO.: | Division of Ser. No. US 1998-212082, filed on 15 Dec 1998 | | |

| | NUMBER | DATE |
|-----------------------|---------------------------------------|---------------|
| PRIORITY INFORMATION: | US 1997-69899P | 19971217 (60) |
| | US 1998-83209P | 19980427 (60) |
| | US 1998-92622P | 19980713 (60) |
| | US 1998-108063P | 19981112 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | GRANTED | |
| PRIMARY EXAMINER: | Shah, Mukund J. | |
| ASSISTANT EXAMINER: | Rao, Deepak R. | |
| LEGAL REPRESENTATIVE: | Durette, Philippe L., Winokur, Melvin | |

NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
LINE COUNT: 4784

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5, and/or .alpha.v.beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 12 OF 20 USPATFULL on STN
ACCESSION NUMBER: 2001:121485 USPATFULL
TITLE: Integrin receptor antagonists
INVENTOR(S): Duggan, Mark E., Schwenksville, PA, United States
Meissner, Robert S., Schwenksville, PA, United States
Perkins, James J., Churchville, PA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|-----------------------|---|------|--------------|
| PATENT INFORMATION: | US 6268378 | B1 | 20010731 |
| APPLICATION INFO.: | US 2000-498895 | | 20000207 (9) |
| RELATED APPLN. INFO.: | Division of Ser. No. US 1998-212123, filed on 15 Dec 1998, now patented, Pat. No. US 6066648, issued on 23 May 2000 | | |

| | NUMBER | DATE |
|-----------------------|---------------------------------------|---------------|
| PRIORITY INFORMATION: | US 1997-69910P | 19971217 (60) |
| | US 1998-83251P | 19980427 (60) |
| | US 1998-92588P | 19980713 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | GRANTED | |
| PRIMARY EXAMINER: | McKane, Joseph K. | |
| ASSISTANT EXAMINER: | Solola, Taofiq A. | |
| LEGAL REPRESENTATIVE: | Durette, Philippe L., Winokur, Melvin | |
| NUMBER OF CLAIMS: | 30 | |
| EXEMPLARY CLAIM: | 1 | |
| LINE COUNT: | 4460 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the vitronectin receptors .alpha.v.beta.3 and/or .alpha.v.beta.5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, viral disease, and tumor growth.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 13 OF 20 USPATFULL on STN
ACCESSION NUMBER: 2001:71543 USPATFULL
TITLE: Beazepine derivatives as .alpha.v integrin receptor antagonists
INVENTOR(S): Askew, Ben C., Lansdale, PA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S.)

corporation)

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|--------------|
| PATENT INFORMATION: | US 6232308 | B1 | 20010515 |
| APPLICATION INFO.: | US 2000-496525 | | 20000202 (9) |

| | NUMBER | DATE |
|-----------------------|---------------------------------------|---------------|
| PRIORITY INFORMATION: | US 1999-118428P | 19990203 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | Granted | |
| PRIMARY EXAMINER: | Shah, Mukund J. | |
| LEGAL REPRESENTATIVE: | Durette, Philippe L., Winokur, Melvin | |
| NUMBER OF CLAIMS: | 15 | |
| EXEMPLARY CLAIM: | 1 | |
| LINE COUNT: | 1967 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to benzazepine derivatives and their use as .alpha.v integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5, and/or .alpha.v.beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 14 OF 20 USPATFULL on STN
ACCESSION NUMBER: 2001:48064 USPATFULL
TITLE: Integrin receptor antagonists
INVENTOR(S): Duggan, Mark E., Schwenksville, PA, United States
Perkins, James J., Churchville, PA, United States
Meissner, Robert S., Schwenksville, PA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|--------------|
| PATENT INFORMATION: | US 6211191 | B1 | 20010403 |
| APPLICATION INFO.: | US 1998-212510 | | 19981215 (9) |

| | NUMBER | DATE |
|-----------------------|---------------------------------------|---------------|
| PRIORITY INFORMATION: | US 1997-69909P | 19971217 (60) |
| | US 1998-83250P | 19980427 (60) |
| | US 1998-92630P | 19980713 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | Granted | |
| PRIMARY EXAMINER: | Raymond, Richard L. | |
| ASSISTANT EXAMINER: | Jayaram, Beby | |
| LEGAL REPRESENTATIVE: | Durette, Philippe L., Winokur, Melvin | |
| NUMBER OF CLAIMS: | 23 | |
| EXEMPLARY CLAIM: | 1 | |
| LINE COUNT: | 3544 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha..nu..beta.3, .alpha..nu..beta.5, and/or .alpha..nu..beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting

vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 15 OF 20 USPATFULL on STN
ACCESSION NUMBER: 2000:92099 USPATFULL
TITLE: Alkanoic acid derivatives as .alpha.v integrin receptor antagonists
INVENTOR(S): Hutchinson, John H., Philadelphia, PA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|--------------|
| PATENT INFORMATION: | US 6090944 | | 20000718 |
| APPLICATION INFO.: | US 1999-371444 | | 19990810 (9) |

| | NUMBER | DATE |
|-----------------------|---------------------------------------|---------------|
| PRIORITY INFORMATION: | US 1998-96378P | 19980813 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | Granted | |
| PRIMARY EXAMINER: | Higel, Floyd D. | |
| LEGAL REPRESENTATIVE: | Durette, Philippe L., Winokur, Melvin | |
| NUMBER OF CLAIMS: | 36 | |
| EXEMPLARY CLAIM: | 1,24 | |
| LINE COUNT: | 3589 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5 and/or .alpha.v.beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, and tumor growth and metastasis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 16 OF 20 USPATFULL on STN
ACCESSION NUMBER: 2000:64874 USPATFULL
TITLE: Integrin receptor antagonists
INVENTOR(S): Duggan, Mark E., Schwenksville, PA, United States
Meissner, Robert S., Schwenksville, PA, United States
Perkins, James J., Churchville, PA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|--------------|
| PATENT INFORMATION: | US 6066648 | | 20000523 |
| APPLICATION INFO.: | US 1998-212123 | | 19981215 (9) |

| | NUMBER | DATE |
|-----------------------|-----------------|---------------|
| PRIORITY INFORMATION: | US 1997-69910P | 19971217 (60) |
| | US 1998-83251P | 19980427 (60) |
| | US 1998-92588P | 19980713 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | Granted | |
| PRIMARY EXAMINER: | Richter, Johann | |

ASSISTANT EXAMINER: Keating, Dominic
LEGAL REPRESENTATIVE: Durette, Philippe L., Winokur, Melvin, Sabatelli,
Anthony D.
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
LINE COUNT: 4780

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the vitronectin receptors .alpha..nu..beta.3 and/or .alpha..nu..beta.5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, viral disease, and tumor growth.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 17 OF 20 USPATFULL on STN
ACCESSION NUMBER: 2000:44101 USPATFULL
TITLE: Integrin receptor antagonists
INVENTOR(S): Askew, Ben C., Lansdale, PA, United States
Coleman, Paul J., Wallingford, PA, United States
Duggan, Mark E., Schwenksville, PA, United States
Halczenko, Wasyl, Lansdale, PA, United States
Hartman, George D., Lansdale, PA, United States
Hunt, Cecilia A., Plymouth Meeting, PA, United States
Hutchinson, John H., Philadelphia, PA, United States
Meissner, Robert S., Schwenksville, PA, United States
Patane, Michael A., Harleysville, PA, United States
Smith, Garry R., Limerick, PA, United States
Wang, Jiabing, Lansdale, PA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|--------------|
| PATENT INFORMATION: | US 6048861 | | 20000411 |
| APPLICATION INFO.: | US 1998-212082 | | 19981215 (9) |

| | NUMBER | DATE |
|-----------------------|-----------------|---------------|
| PRIORITY INFORMATION: | US 1997-69899P | 19971217 (60) |
| | US 1998-83209P | 19980427 (60) |
| | US 1998-92622P | 19980713 (60) |
| | US 1998-108063P | 19981112 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Shah, Mukund J.
ASSISTANT EXAMINER: Rao, Deepak R.
LEGAL REPRESENTATIVE: Durette, Philippe L., Winokur, Melvin, Sabatelli,
Anthony

NUMBER OF CLAIMS: 47
EXEMPLARY CLAIM: 1
LINE COUNT: 5443

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5, and/or .alpha.v.beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor

growth, and metastasis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 18 OF 20 USPATFULL on STN
ACCESSION NUMBER: 2000:34557 USPATFULL
TITLE: Integrin receptor antagonists
INVENTOR(S): Duggan, Mark E., Schwenksville, PA, United States
Hartman, George D., Lansdale, PA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S.
corporation)

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|--------------|
| PATENT INFORMATION: | US 6040311 | | 20000321 |
| APPLICATION INFO.: | US 1999-362528 | | 19990728 (9) |

| | NUMBER | DATE |
|-----------------------|---|---------------|
| PRIORITY INFORMATION: | US 1998-94478P | 19980729 (60) |
| DOCUMENT TYPE: | Utility | |
| FILE SEGMENT: | Granted | |
| PRIMARY EXAMINER: | Dentz, Bernard | |
| LEGAL REPRESENTATIVE: | Durette, Philippe L., Winokur, Melvin, Sabatelli,
Anthony D. | |
| NUMBER OF CLAIMS: | 33 | |
| EXEMPLARY CLAIM: | 1 | |
| LINE COUNT: | 2801 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha..nu..beta.3, .alpha..nu..beta.5 and/or .alpha..nu..beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, and tumor growth and metastasis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 19 OF 20 USPATFULL on STN
ACCESSION NUMBER: 2000:9915 USPATFULL
TITLE: Integrin receptor antagonists
INVENTOR(S): Askew, Ben C., Lansdale, PA, United States
Coleman, Paul J., Wallingford, PA, United States
Duggan, Mark E., Schwenksville, PA, United States
Halczenko, Wasyl, Lansdale, PA, United States
Hutchinson, John H., Philadelphia, PA, United States
Meissner, Robert S., Schwenksville, PA, United States
Patane, Michael A., Harleysville, PA, United States
Wang, Jiabing, Lansdale, PA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S.
corporation)

| | NUMBER | KIND | DATE |
|---------------------|----------------|------|--------------|
| PATENT INFORMATION: | US 6017926 | | 20000125 |
| APPLICATION INFO.: | US 1998-212079 | | 19981215 (9) |

| | NUMBER | DATE |
|-----------------------|----------------|---------------|
| PRIORITY INFORMATION: | US 1997-69910P | 19971217 (60) |
| | US 1998-83251P | 19980427 (60) |

| | |
|-----------------------|--|
| US 1998-92588P | 19980713 (60) |
| US 1998-79197P | 19980324 (60) |
| US 1998-79944P | 19980330 (60) |
| US 1998-80397P | 19980402 (60) |
| US 1998-92624P | 19980713 (60) |
| US 1998-99948P | 19980911 (60) |
| DOCUMENT TYPE: | Utility |
| FILE SEGMENT: | Granted |
| PRIMARY EXAMINER: | Dentz, Bernard |
| LEGAL REPRESENTATIVE: | Durette, Philippe L., Winokur, Melvin, Sabatelli, Anthony D. |
| NUMBER OF CLAIMS: | 48 |
| EXEMPLARY CLAIM: | 1 |
| LINE COUNT: | 5668 |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5 and/or .alpha.v.beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, and tumor growth and metastasis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 20 OF 20 EUROPATFULL COPYRIGHT 2003 WILA on STN

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

| ACCESSION NUMBER: | 1228761 EUROPATFULL EW 200232 FS OS | | | | | | | | | | | | |
|---------------------------------------|--|-----------|-----------|------------|-------------------------|----------------------|--|---------------------------------|----------|---------------------------------------|----------|----------------|----------|
| TITLE: | Liquid pharmaceutical composition for treating bone diseases.
Fluessige pharmazeutische Zusammensetzung zur Behandlung von Knochenerkrankungen.
Composition pharmaceutique liquide pour le traitement de maladies osseuses. | | | | | | | | | | | | |
| INVENTOR(S): | Uria, Guadalupe Martinez, Avenida Juan B. Justo 4840 (1416), Capital Federal, AR | | | | | | | | | | | | |
| PATENT ASSIGNEE(S): | Riderway Corporation, Elvira Mendez, Edificio Villarino, Piso 6, Panama, PA | | | | | | | | | | | | |
| PATENT ASSIGNEE NO: | 4010580 | | | | | | | | | | | | |
| AGENT: | Frohwitter, Bernhard, Dipl.-Ing., Patent- und Rechtsanwaelte, Postfach 86 03 68, 81630 Muenchen, DE | | | | | | | | | | | | |
| AGENT NUMBER: | 150675 | | | | | | | | | | | | |
| OTHER SOURCE: | BEP A2002066 EP 1228761 A2 0011 | | | | | | | | | | | | |
| SOURCE: | Wila-EPZ-2002-H32-T1b | | | | | | | | | | | | |
| DOCUMENT TYPE: | Patent | | | | | | | | | | | | |
| LANGUAGE: | Anmeldung in Englisch; Veroeffentlichung in Englisch | | | | | | | | | | | | |
| DESIGNATED STATES: | R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE; R TR; R AL; R LT; R LV; R MK; R RO; R SI | | | | | | | | | | | | |
| PATENT INFO.PUB.TYPE: | EPA2 EUROPÄISCHE PATENTANMELDUNG | | | | | | | | | | | | |
| PATENT INFORMATION: | <table> <thead> <tr><th>PATENT NO</th><th>KIND DATE</th></tr> </thead> <tbody> <tr><td>EP 1228761</td><td>A2 20020807
20020807</td></tr> <tr><td>'OFFENLEGUNGS' DATE:</td><td></td></tr> <tr><td>APPLICATION INFO.: EP 2002-1959</td><td>20020201</td></tr> <tr><td>PRIORITY APPLN. INFO.: US 2001-265827</td><td>20010201</td></tr> <tr><td>AR 2001-106109</td><td>20011228</td></tr> </tbody> </table> | PATENT NO | KIND DATE | EP 1228761 | A2 20020807
20020807 | 'OFFENLEGUNGS' DATE: | | APPLICATION INFO.: EP 2002-1959 | 20020201 | PRIORITY APPLN. INFO.: US 2001-265827 | 20010201 | AR 2001-106109 | 20011228 |
| PATENT NO | KIND DATE | | | | | | | | | | | | |
| EP 1228761 | A2 20020807
20020807 | | | | | | | | | | | | |
| 'OFFENLEGUNGS' DATE: | | | | | | | | | | | | | |
| APPLICATION INFO.: EP 2002-1959 | 20020201 | | | | | | | | | | | | |
| PRIORITY APPLN. INFO.: US 2001-265827 | 20010201 | | | | | | | | | | | | |
| AR 2001-106109 | 20011228 | | | | | | | | | | | | |

EAST

| | Inventor | S | C | P | 2 | 3 | 4 | 5 | Image Doc.
Displayed | PT |
|---|------------------------------|-------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|-------------------------|--------------------------|
| 1 | Urias, Guadalupe
Martinez | <input checked="" type="checkbox"/> | <input type="checkbox"/> | US 20020142997 | <input type="checkbox"/> |

Freeform Search

| | |
|---|--|
| Database: | <input type="checkbox"/> US Pre-Grant Publication Full-Text Database
<input type="checkbox"/> US Patents Full-Text Database
<input checked="" type="checkbox"/> US OCR Full-Text Database

Term:
<input type="text" value="L6 and (quartnerary ammoni?)"/> <div style="float: right; margin-top: -20px;">

 </div> |
| Display: | <input type="text" value="10"/> Documents in <u>Display Format:</u> <input type="text"/> Starting with Number <input type="text" value="1"/> |
| Generate: <input type="radio"/> Hit List <input checked="" type="radio"/> Hit Count <input type="radio"/> Side by Side <input type="radio"/> Image | |

Search History

DATE: Friday, September 05, 2003 [Printable Copy](#) [Create Case](#)

| <u>Set</u>
<u>Name</u> | <u>Query</u> | <u>Hit</u>
<u>Count</u> | <u>Set</u>
<u>Name</u> |
|--|--|----------------------------|---------------------------|
| side by side | | | result set |
| <u>DB=PGPB,USPT,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</u> | | | |
| <u>L7</u> | L6 and (quartnerary ammoni?) | 11 | <u>L7</u> |
| <u>L6</u> | L5 and ((polyethylene glycol) or (hydroxy stearic) or (acid glyceride?)) | 34 | <u>L6</u> |
| <u>L5</u> | L3 and (deionized water) | 34 | <u>L5</u> |
| <u>L4</u> | L3 and (nipagin or nipasol) | 1 | <u>L4</u> |
| <u>L3</u> | L2 and ((propylene glycol) or glerol or glycol\$) | 35 | <u>L3</u> |
| <u>L2</u> | L1 and (acetate? or citrate? or ascorbate? or phosphate?) | 36 | <u>L2</u> |
| <u>L1</u> | ibandron\$ and (osteogen\$ or bone or osseous or skeletal\$) | 253 | <u>L1</u> |

END OF SEARCH HISTORY

| | Type | L # | Hits | Search Text | DBs | Time Stamp |
|---|------|-----|------|--|--|---------------------|
| 1 | BRS | L1 | 253 | ibandron\$ and (osdtegen\$ or
bone or osseous or
skeletal\$) | USPAT;
US - PGP
UB;
EPO;
JPO;
DERWEN
T;
IBM_TD
B | 2003/09/05
19:38 |
| 2 | BRS | L2 | 253 | ibandron\$ and (osteogen\$ or
bone or osseous or
skeletal\$) | USPAT;
US - PGP
UB;
EPO;
JPO;
DERWEN
T;
IBM_TD
B | 2003/09/05
19:39 |
| 3 | BRS | L3 | 148 | 12 and (acetate? or citrate?
or ascorbate? or
phosphate?) | USPAT;
US - PGP
UB;
EPO;
JPO;
DERWEN
T;
IBM_TD
B | 2003/09/05
19:39 |
| 4 | BRS | L4 | 148 | 13 and ((propylene glycol)
or glycerol or glycol\$ or
(polyethylene glycol) or
(acid glyceride?)) | USPAT;
US - PGP
UB;
EPO;
JPO;
DERWEN
T;
IBM_TD
B | 2003/09/05
19:41 |
| 5 | BRS | L5 | 1 | 14 and (nipagin or nipasol
or borate? or boric?) | USPAT;
US - PGP
UB;
EPO;
JPO;
DERWEN
T;
IBM_TD
B | 2003/09/05
19:42 |

| | Comments | Error Definition | Errors |
|---|----------|------------------|--------|
| 1 | | | 0 |
| 2 | | | 0 |
| 3 | | | 0 |
| 4 | | | 0 |
| 5 | | | 0 |

| | Title | Current OR | Current XRef | Retrieval Classif |
|---|--|------------|--------------|-------------------|
| 1 | Liquid pharmaceutical composition for treating bone diseases | 514/102 | | |

| | U | 1 | Document ID | Issue Date | Pages |
|---|--------------------------|--------------------------|----------------------|------------|-------|
| 1 | <input type="checkbox"/> | <input type="checkbox"/> | US 20020142997
A1 | 20021003 | 7 |